Emergent BioSolutions Inc. (LON:0IGA)
5.67
-0.30 (-5.03%)
At close: Aug 1, 2025
Emergent BioSolutions Revenue
Emergent BioSolutions had revenue of $222.20M USD in the quarter ending March 31, 2025, a decrease of -26.03%. This brings the company's revenue in the last twelve months to $965.40M, down -18.56% year-over-year. In the year 2024, Emergent BioSolutions had annual revenue of $1.04B, down -0.54%.
Revenue (ttm)
$965.40M
Revenue Growth
-18.56%
P/S Ratio
0.31
Revenue / Employee
$1.07M
Employees
900
Market Cap
230.70M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.04B | -5.70M | -0.54% |
Dec 31, 2023 | 1.05B | -68.20M | -6.10% |
Dec 31, 2022 | 1.12B | -656.10M | -36.99% |
Dec 31, 2021 | 1.77B | 196.30M | 12.45% |
Dec 31, 2020 | 1.58B | 471.30M | 42.61% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.64B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.50B |
HUTCHMED (China) | 503.39M |
Oxford Nanopore Technologies | 183.19M |
Emergent BioSolutions News
- 5 days ago - Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. House of Representatives - GlobeNewsWire
- 5 days ago - New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox - GlobeNewsWire
- 18 days ago - Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025 - GlobeNewsWire
- 24 days ago - Emergent BioSolutions (EBS) Expands Smallpox Vaccine Contract with US Government - GuruFocus
- 24 days ago - Emergent BioSolutions signs contract modification award for CNJ-016 - Seeking Alpha
- 24 days ago - Emergent Biosolutions secures $51.9M contract modification award for smallpox preparedness - Seeking Alpha
- 24 days ago - Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts - GlobeNewsWire
- 4 weeks ago - Emergent BioSolutions Expands NARCANDirect® to Offer KLOXXADO® (naloxone HCl) Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate - GlobeNewsWire